

IFW



Attorney's Docket No. 046562/274659

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Fraser <i>et al.</i>	Confirmation No.:	4482
App. No.:	10/769,952	Group Art Unit:	1614
Filed:	March 10, 2004	Examiner:	Not yet assigned
For:	METHODS FOR TREATING LOWER URINARY TRACT DISORDERS AND THE RELATED DISORDERS VULVODYNIA AND VULVAR VESTIBULITIS USING CAV2.2 SUBUNIT CALCIUM CHANNEL MODULATORS		

September 16, 2004

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
CITATION UNDER 37 C.F.R. § 1.97

Sir:

Attached is a list of documents on form PTO-1449. In accordance with the Office waiver published July 11, 2003, copies of the cited U.S. patents and patent application publications are not enclosed. Applicant does enclose copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Applicant notes that each item of information listed on form PTO-1449 was cited in a communication from a foreign patent office in a counterpart foreign application. In addition, the communication from the foreign patent office was not received by any individual designated by 37 CFR 1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

*Edward R. Ergenzinger Jr.*  
Edward R. Ergenzinger, Jr.  
Registration No. 47,549

<p>CUSTOMER NO. 00826 ALSTON &amp; BIRD LLP Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200 Fax Raleigh Office (919) 862-2260</p>	<p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on September 16, 2004 <i>Lyndee Jo Pixley</i> Lyndee Jo Pixley</p>
---	---

Substitute for form 1449/PTO  
(Revised 04/2003)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

## Complete if Known

Application Number 10/769,958  
Filing Date March 10, 2004  
First Named Inventor Fraser  
Group Art Unit 1614  
Examiner Name Not yet assigned  
Attorney Docket Number 046562/274659

## U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	US-5,698,549	12-16-1997	Steers <i>et al.</i>	
	2	US-5,670,622	9-23-1997	Shon <i>et al.</i>	
	3	US-5,739,276	4-14-1998	Shon <i>et al.</i>	
	4	US-6,077,680	6-20-2000	Kem <i>et al.</i>	
	5	US-6,190,691	2-20-2001	Mak	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	6	WO 95/23132	08-31-1995	Cambridge Neuroscience, Inc.		
	7	WO 96/33206	10-24-1996	University of Utah Research Foundation		
	8	WO 98/23639	06-04-1998	University of Florida <i>et al.</i>		
	9	JP 11035483	02-19-1999	Nippon Kayaku Co. Ltd.		
	10	WO 99/28342	06-10-1999	Sibia Neurosciences, Inc.		
	11	WO 00/18801	04-06-2000	Ronn <i>et al.</i>		
	12	WO 00/18402	04-06-2000	Merck & Co., Inc.		
	13	EP 1 042 468 A2	10-11-2000	Mark <i>et al.</i>		
	14	EP 1 117 680 A2	07-25-2001	Ronn <i>et al.</i>		
	15	WO 03/018561 A1	03-06-2003	Astrazeneca AB		
	16	WO 2004/054560 A1	07-01-2004	Warner-Lambert Company LLC		

Substitute for form 1449/PTO  
(Revised 04/2003)

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	2	of	2	Examiner Name	Not yet assigned
				Attorney Docket Number	046562/274659

## **Complete if Known**

Application Number	10769,958
Filing Date	March 10, 2004
First Named Inventor	Fraser
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	046562/274659

## **OTHER DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	17	CATTERALL, W.A., "Structure and Regulation of Voltage-Gated Ca <sup>2+</sup> Channels," <i>Annu. Rev. Cell Dev. Biol.</i> , 2000, pp. 521-555, Vol. 16.	
	18	GUIDO, M. III, <i>et al.</i> , "Clinical Experience with Levetiracetam," <i>Epilepsia</i> , 2001, p. 180, Vol. 42(7).	
	19	MAGGI, C.A., <i>et al.</i> , "Effect of Omega Conotoxin on Reflex Responses Mediated by Activation of Capsaicin-Sensitive Nerves of the Rat Urinary Bladder and Peptide Release from the Rat Spinal Cord," <i>Neuroscience</i> , 1990, pp. 243-250, vol. 34(1).	
Examiner Signature			Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.